Jove
Visualize
Contact Us

Related Experiment Videos

Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical

J B Jackson1

  • 1Institute of Pathology and Department of Geographic Medicine, Case Western Reserve University, University Hospitals of Cleveland, OH, USA.

Pediatric AIDS and HIV Infection
|December 1, 1995
PubMed
Summary

Zidovudine (AZT) reduces HIV-1 viral load in pregnant women, but significant drops take 24-48 hours. Administer AZT at least two days before delivery to effectively lower maternal viral load and prevent transmission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-TB lung function, quality of life, and radiographic findings in children.

IJTLD open·2025
Same author

Conducting interslice stimulation for concurrent TMS-fMRI.

Journal of neuroscience methods·2025
Same author

Domain general frontoparietal regions show modality-dependent coding of auditory and visual rules.

bioRxiv : the preprint server for biology·2024
Same author

Predictors of mortality in Ugandan children with TB, 2016-2021.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

Seroprevalence of unexpected red blood cell antibodies among pregnant women in Uganda.

Immunohematology·2013
Same author

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.

Blood cancer journal·2012
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Background:

  • Zidovudine (AZT) use in pregnant women shows promise in reducing vertical human immunodeficiency virus type 1 (HIV-1) transmission.
  • This reduction may be linked to decreased maternal viral load.

Purpose of the Study:

  • To determine the time course of viral load reduction following the initiation of oral AZT therapy.
  • To inform optimal timing for AZT administration in pregnant individuals to prevent HIV-1 transmission.

Main Methods:

  • Sequential measurement of plasma HIV-1 RNA and infectious virus levels at hourly intervals post-AZT initiation.
  • Quantitative HIV-1 RNA, p24 antigen, and AZT levels measured at various time points (hours to 1 week).
  • Peripheral blood mononuclear cell and plasma cultures, CD4 counts, and MT-2 cell assays performed at baseline and up to 1 week.

Related Experiment Videos

Main Results:

  • A significant reduction in viral load was not observed until 24-48 hours after starting AZT therapy.
  • Viral load, p24 antigen, and AZT levels were monitored over time.

Conclusions:

  • AZT administration should occur at least 2 days prior to delivery to ensure a significant reduction in maternal viral load.
  • This timing may be crucial for AZT's efficacy in preventing vertical HIV-1 transmission.